Critical Values July 2015
ePolicy 300x175

Global Community: ASCP Scores in the Battle Against Cervical Cancer

Monday, January 7, 2013

  • Since 2005 through funding from the Centers for Disease Control and Prevention (CDC), ASCP has engaged members who are laboratory professionals to work in 19 countries within the President’s Emergency Plan for AIDS Relief (PEPFAR) for improving laboratory standards to ultimately achieve accreditation and to enhance training of laboratory professionals. These efforts are improving the diagnosis for all diseases, including cervical cancer.

  • ASCP collaborated with several medical societies, including the American Cancer Society (ACS) and the American Society for Colposcopy and Cervical Pathology (ASCCP), to update Guidelines for Cervical Cancer Screening in 2012. The new Guidelines were published in the April 2012 issue of American Journal of Clinical Pathology and focus on doing what is best for women at every life stage, regardless of cost. Also, see a summary of the Guidelines in the April 2012 issue of Critical Values (p.29).

  • The revised Guidelines for Cervical Cancer Screening are based on systematic evidence review, contributions from six working groups, which included ASCP member pathologists and clinical scientists, and a symposium cosponsored by ASCP, ACS, and ASCCP and attended by 25 organizations.

  • The new screening recommendations encompass age-appropriate screening strategies, including the use of cytology (Pap test) and high-risk HPV testing alone or in combination, follow-up testing for women after screening, including the use of genotyping, and future considerations for HPV testing alone, as well as screening strategies for women vaccinated against HPV.

  • During the past 60 years, regular Pap testing and treatment of the women with abnormalities has been responsible for cervical cancer dropping from being the No. 1 cause of cancer death among women, to a rank of 14 for all cancer deaths in the United States.1 Despite these advances, in 2011 an estimated 12,710 cases of invasive cervical cancer were diagnosed and an estimated 4,290 women died in the United States.2 Pap testing is less effective in identifying women who are at risk of adenocarcinoma, a rarer histologic type of cervical cancer than squamous cell carcinoma, but one that represents approximately 20 percent of cervical cancers in the United States.

  • Scientists and physicians know that persistent cervical infection with high-risk HPV genotypes is necessary for the development of cervical cancer and its immediate precursor lesion cervical intraepithelial neoplasia grade 3 (CIN3). It is clearly the treatment of precancer (CIN3) that prevents the development of cancer, and the process that led to the revised guidelines focused on how to best identify patients with precancer who need treatment while minimizing the potential harms to patients from extensive screening.

  • Two types of cervical cancer screenings, the Pap test and molecular tests for HPV, often work well in tandem. The Pap test has successfully lowered cervical cancer deaths. However, false-negative results are common, and any single test is not as sensitive as previously thought for detecting CIN3. On the other hand, HPV tests are more sensitive than the Pap test for precancer and may also be better at forecasting which women will develop CIN3+ over the next five to 15 years.3

Here are scientists’ key recommendations from the Guidelines for Cervical Cancer:

  • Cervical cancer screening should begin at age 21.

  • Women 21 to 29 years old should be screened with Pap test alone every three years.

  • Women 30 to 65 years old should be screened with Pap and HPV tests (co-testing) every five years (preferred) or with Pap test every three years (acceptable).

  • Women who co-test HPV positive but cytology negative should be followed with either (1) repeat co-testing within 12 months or (2) immediate HPV genotype-specific testing for HPV 16 alone or for HPV 16 and HPV 18. If co-testing is repeated at 12 months, women testing positive on either test should be referred to colposcopy; women testing negative on both tests should return to routine screening.

  • In most clinical settings, women ages 30 to 65 years old should not be screened with HPV testing alone as an alternative to co-testing at five-year intervals or Pap test alone at three-year intervals.

  • Women at age 65 with adequate negative screening in the last 10 years and no history of cancer may stop screening.

  • Women at any age following a hysterectomy with removal of the cervix who have no history of CIN2+ should not be screened for vaginal cancer using any modality.

  • Recommended screening practices should not change on the basis of HPV vaccination status.

  • At the 2011 ASCP Annual Meeting, a general session “Global Access to Health Care: Taking a Closer Look at Cervical Cancer” addressed the challenges and successes involved in establishing equal access to quality health care with a focus on cervical cancer screening and treatment worldwide. The distinguished panel of experts included Doreen Ramogla-Masire, MD, BMed Sci, BMBS, FCOG, from Botswana; Debra Graves, MD, MBBS, MHA, FRACMA; John Tomaszewski, MD, FASCP, 2010–2011 ASCP President; and Tamika Felder, a cervical cancer survivor.


  1. Saslow D, Solomon D, Herschel W, et al. American Cancer Society, American Society for Colopscopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. Am J Clin Pathol. 2012;137:4:516–542.

  2. Centers for Disease Control and Prevention, Department of Health and Human Services. Statistics and surveillance: 2009 adult vaccination coverage, NHIS—The National Health Interview Survey. March 2, 2011. Available at: Accessed Feb. 1, 2012.

  3. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: A Cancer Journal for Clinicians. 2011;61(4):212–236.